Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924101 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT04924101 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 126 participants.
The verdict
NCT04924101, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Etoposide
- DRUG Lenvatinib
- BIOLOGICAL MK-4830
- BIOLOGICAL Boserolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2025-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924101
The ClinicalTrials.gov registry entry for NCT04924101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04924101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04924101 about?
NCT04924101 is a clinical study titled "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)". The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cance...
What is the current status of trial NCT04924101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2021-07-15. Estimated completion is 2025-06-23.
What interventions are being tested in trial NCT04924101?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Etoposide (DRUG), Lenvatinib (DRUG), MK-4830 (BIOLOGICAL), Boserolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04924101?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.